Biosimilar Filgrastim Use in the United States vs the European Union and Japan

This Viewpoint discusses obstacles that limit the use of biosimilar filgrastim in the United States compared with countries in the European Union and Japan and discusses strategies that might help biosimilar filgrastim use become more widespread.

https://ift.tt/2QcfTGE